US Patent Issued to Brookhaven Lab, BioSet

Brookhaven Science Associates, which operates and manages the US Department of Energy’s Brookhaven National Laboratory, and Biosurface Engineering Technologies Inc. (BioSet) have been issued a US patent for a synthetic peptide called B2A. A medical device called Amplex has been developed that incorporates B2A osteoinductive growth factor with an ultrahigh-grade ceramic bone substitute for use in surgery. The FDA has approved a pilot study of 22 patients by BioSet to evaluate the safety and preliminary efficacy of the device.